CTIS2022-502956-29-00招募中1 期
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) - CAAA617D12302
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Histologically confirmed prostate cancer prior to randomization, Participants must have biochemically recurrent disease after definitive treatment to prostate by RP, (alone or with post-operative radiation to prostate bed/pelvic nodes) or XRT, (prostate alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy prior to randomization. Biochemical recurrence is defined as: nadir PSA + 2 ng/mL post XRT (if participant received-radiation therapy to intact prostate) and PSA > 0.2 ng/mL and rising post RP (with or without post-operation RT), Participants must have OMPC with =5 PSMA-positive metastatic lesions on screening PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as visually assessed by BIRC based on the methodology proposed in the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE v2) (Seifert et al 2023); for further details, please refer to Section 8.1 and Imaging Manual. Metastatic lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a), bone (M1b), lung and others visceral (M1c) except liver and brain classified using AJCC 8. When counting the number of oligometastatic lesions, each lesion is counted as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and one extra-pelvic lymph node will be counted as two metastatic lesions), At least 1 PSMA-positive lesion should be a distant metastasis (M1) per AJCC8 classification at screening. For AJCC M staging, PSMA PET information should be used, Participants must have a negative conventional imaging for M1 disease at screening. Note: •For a participant not to be eligible, CI positive M1 lesions should be unequivocal in CI scans, i.e., potentially not attributable to findings thought to represent something other than tumor (e.g., degenerative, or post-traumatic changes or Paget’s disease in bone lesions). For conventional imaging assessments, bone lesions must be assessed by bone scan only and soft tissue lesions must be assessed by CT/MRI scans only at screening . •Prior knowledge of PSMA PET positivity should not influence the radiologist (reader) in determination of CI positivity. Two different readers will be involved, one reader for PSMA PET scan and one reader for CI: Reader will be blinded to PSMA PET scan results while reading CI scans. Readers should not modify their assessment of CI scans (e.g. changing a lesion previously identified as equivocal in CI to unequivocal) after reading the PSMA PET scan. Similarly, biopsy positivity should not influence the reader in the assessment of CI positivity. More details on the reading paradigm will be provided in the imaging charter. •MRI for radiation treatment planning may show M1 disease but this will not exclude the participant from the study if the lesion is deemed negative per baseline CT or bone scans. •Participants with pelvic disease (N1) seen in conventional imaging are allowed if the local spread is below common iliac bifurcation (per AJCC 8 definition of local disease). •Distant lymph node disease (M1a) that is visible per CI and less than 10mm in the short axis are not exclusionary irrespective of PSMA PET positivity. • If a previously surgically removed lesion was unequivocal for M1 by bone scan or CT, the participant is not eligible, All metastatic lesions detected at screening should be amenable to SBRT, Non-castration testosterone level >100 ng/dL at screening
排除标准
- •Participants with de novo OMPC at screening, Unmanageable concurrent bladder outflow obstruction or urinary incontinence at screening. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed, Prior therapy with: a.ADT including bilateral orchiectomy •Participants who had XRT or RP and completed adjuvant ADT (or ADT+ Androgen Receptor Pathway Inhibitor (ARPI)) prior to recurrence are eligible to participate if the last dose of ADT (or ADT+ARPI) was before 12 months from randomization. Participants who had prior SBRT with short term ADT (3-6 months) are also allowed if the ADT was stopped at least 12 months before randomization . •Participants who discontinued ADT due to disease progression are not allowed (i.e., CRPC participants) b.Other hormonal therapy. e.g., •Use of estrogens, 5-a reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethamide) if used in the context of prostate cancer treatment. Same medications are allowed if used for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if stopped at least 5 half-lives before randomization. •First-generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone). •Second generation anti-androgens (e.g., enzalutamide, apalutamide and darolutamide) •CYP17 inhibitors (e.g., abiraterone acetate, orteronel, galeterone, ketoconazole). Short term ketoconazole treatment (<28 days) is permitted. c.Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand therapy) d.Immunotherapy (e.g., sipuleucel-T) e.Chemotherapy, except if administered in the adjuvant/neoadjuvant setting completed > 12 months before randomization f.Any other investigational or systemic agents for metastatic disease, Radiation therapy, external beam radiation therapy (EBRT), and brachytherapy within 28 days before randomization, Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal therapy (see ADT initiation guidance in Section 6.8.2), PARP inhibitor, biological therapy, or investigational therapy, Diagnosed at screening with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease/treatment free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer, History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as: •Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker •History of familial long QT syndrome or known family history of Torsades de Pointe •, Participants in immediate need of ADT as assessed by the investigator.
研究者
相似试验
尚未招募
3 期
PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC.Oligometastatic Prostate Cancer (OMPC) by PSMA PET, M1 negative by CI.JPRN-jRCT2031230608Yamauchi Kyosuke20
进行中（未招募）
不适用
A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines - NT-SPUTNIKEUCTR2008-000549-73-DEMerz Pharmaceuticals GmbH101
招募中
4 期
Study of VIVO ISAR stent in patients undergoing percutaneous coronary intervention with short dual-anti-platelet therapyCTRI/2024/01/061159Translumina Therapeutics LLP
招募中
1 期
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan alone and lutetium [177Lu] vipivotide tetraxetan in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-503040-41-00ovartis Pharma AG120
进行中（未招募）
1 期
HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.EUCTR2014-000650-11-ESPromethera Biosciences6